The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock Newsletter
ChartZero.com
ChartZero

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Sun., Mar. 26, 2:55 PM

Slide #8. Bellicum Pharmaceuticals, Inc. Secondary Offering

Company: Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM)
Date announced: 3/22/2017
Shares Offered: 5,000,000
Date of Pricing: 3/23/2017
Price Per Share: $12.00
Secondary Offering Details: Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM) today announced that it has commenced an underwritten public offering of 5,000,000 shares of its common stock. Bellicum expects to grant the underwriters of the offering a 30-day option to purchase up to an additional 750,000 shares of its common stock at the public offering price, less the underwriting discounts and commissions. All shares of common stock to be sold in the offering will be offered by Bellicum. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. -updated 3/23- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM) today announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a price to the public of $12.00 per share. The aggregate offering size, before deducting the underwriting discounts and commissions and other offering expenses, is expected to be approximately $60.0 million. The offering is expected to close on or about March 29, 2017, subject to customary closing conditions. In addition, the underwriters have been granted a 30-day option to purchase up to an additional 750,000 shares of its common stock at the public offering price, less the underwriting discounts and commissions.

Bellicum Pharmaceuticals is a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for various forms of cancer, including both hematological cancers and solid tumors, as well as orphan inherited blood disorders. Co.'s primary product candidate, BPX-501, is an adjunct T-cell therapy administered after allogeneic hematopoietic stem cell transplantation, using genetically modified donor T cells incorporating Co.'s CaspaCIDe® safety switch. BPX-501 is being evaluated in multiple Phase 1/2 clinical trials in adults and pediatric patients with leukemias, lymphomas, and genetic blood diseases in the U.S. and Europe.

BLCM SEC Filing Email Alerts Service

Open the BLCM Page at The Online Investor »

Company Name:  Bellicum Pharmaceuticals Inc
Website:  www.bellicum.com
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding BLCM:  18
Total Market Value Held by ETFs:  $14.08M
Total Market Capitalization:  $390.00M
% of Market Cap. Held by ETFs:  3.61%
 

Open the BLCM Page at The Online Investor (in a new window) »

March 26, 2017    2:55 PM Eastern
Quotes delayed 20 minutes



Strong Buy (3.86 out of 4)
82nd percentile
(ranked higher than approx. 82% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | www.TheOnlineInvestor.com | Copyright © 1998 - 2017, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.